B. Riley Financial Varied
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

44.04 +0.14 (+0.32%)
Official Closing Price Updated: 7:00 PM EDT, May 7, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 11,026,927
Open 43.98
Bid (Size) 43.98 (1)
Ask (Size) 44.04 (13)
Prev. Close 43.90
Today's Range 43.84 - 44.26
52wk Range 43.33 - 69.10
Shares Outstanding 2,222,113,553
Dividend Yield 5.18%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Top 4 Health Care Stocks Which Could Rescue Your Portfolio This Month
Via Benzinga

Performance

YTD
-16.53%
-16.53%
1 Month
-13.82%
-13.82%
3 Month
-10.60%
-10.60%
6 Month
-15.78%
-15.78%
1 Year
-35.62%
-35.62%

More News

Read More
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
From Bristol Myers Squibb
Via Business Wire
Maximize Your Dividends: 7 Stocks Trading Under $50 with 5%+ Yields
Via InvestorPlace
A Closer Look at Bristol-Myers Squibb's Options Market Dynamics
Via Benzinga
How Is The Market Feeling About Bristol-Myers Squibb?
Via Benzinga
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
Via Benzinga
Topics Stocks
Exposures US Equities
Why Bristol Myers Squibb Stock Is Sinking Today
Via The Motley Fool
U.S. Food and Drug Administration Accepts Bristol Myers Squibb’s Application for Subcutaneous Nivolumab (nivolumab and hyaluronidase)
From Bristol Myers Squibb
Via Business Wire
European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite...
From Bristol Myers Squibb
Via Business Wire
Uncover the Potential: 3 Discounted Stocks Ready for a Comeback
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Could Investing $100,000 in Bristol Myers Squibb Stock Make You a Millionaire?
Via The Motley Fool
If You'd Invested $1,000 in Bristol Myers Squibb 5 Years Ago, Here's How Much You'd Have Today
Via The Motley Fool
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
From Editas Medicine, Inc.
Via GlobeNewswire
3 Top ETFs to Buy for Passive Income in May
Via The Motley Fool
Topics ETFs
Last Week's Worst-Performing Stocks: Are These 10 Large-Cap Stocks In Your Portfolio? (April 21-27, 2024)
Via Benzinga
Peeling Back The Layers: Exploring Bristol-Myers Squibb Through Analyst Insights
Via Benzinga
Stock Market Rebounds; Tesla, Microsoft, Google, Meta, Chipotle, GE In Focus: Weekly Review
Via Investor's Business Daily
CHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb’s Opdivo® (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
From Bristol Myers Squibb
Via Business Wire
Investor Sentiment Improves Slightly, But Dow Tumbles Over 350 Points
Via Benzinga
Topics Stocks
Exposures US Equities
Crude Oil Moves Higher; Bristol Myers Squibb Shares Fall After Q1 Results
Via Benzinga
Exposures Fossil Fuels
Why Caterpillar Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Bristol Myers Squibb Swings To Quarterly Loss, After String Of Multi-Billion Acquisitions
Via Benzinga
PLTR Stock: Palantir Beefs Up Healthcare AI Work Through Parexel Deal
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
B. Riley Financial's diverse suite of services goes beyond traditional financial service offerings. By leveraging cross-platform expertise and assets, B. Riley Financial companies are uniquely positioned to provide full service, collaborative solutions to our clients at every stage of the business life cycle and in all market conditions.

B. Riley refers to B. Riley Financial, Inc. and/or one or more of its subsidiaries or affiliates. Click here for further details.